Bill Henshaw, Axcella Health CEO
December 15, 2022 08:24 AM EST
Coronavirus

Ax­cel­la re­duces work­force by 85%, pri­or­i­tizes long Covid drug re­search

Katherine Lewin

News Reporter

Af­ter miss­ing its pri­ma­ry goal in Phase IIa tri­als for its long Covid drug, Ax­cel­la Health an­nounced Wednes­day that it’s cut­ting 85% of its work­force …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times